Review
Open access
Jul 2026
DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives
Delta-like ligand 3-directed therapies may reshape the management of DLL3-expressing prostate cancer if ongoing efforts to refine biomarkers improve patient enrichment and optimize trial design are successfully translated into clinical practice.
Giovanna Pecoraro, A. De Giorgi, G. Montelatici et al.
· Drugs · 0 citations